. In contrast, we can hypothesize that this threshold dyadic Ca 2+ level is reached in heart failure due to a less extreme leak in combination with reduced SERCA2a activity ( Figure 1A) . However, the SR abnormalities observed in the more common clinical problem of acquired heart failure are very different mechanistically, and therefore caution must be considered before over-interpretation of the results from these genetic models are applied to strategies to target the SR in acquired heart failure. The first and most critical issue is that the abnormalities of SR Ca 2+ uptake and release in heart failure are potentially reversible. Changes in gene expression and posttranslational modifications of SERCA2a, phospholamban, and RyR can be partially or completely normalized by treatments that effectively correct the remodelling of the failing heart, underpinning the plasticity of the system. In addition to established interventions, there is recent growing interest in targeting the SR abnormalities directly using RyR stabilizers or SERCA2a gene transfer. In contrast to the genetic SR models, which cannot be corrected by up-regulation of SERCA2a activity, and are actually exacerbated as reported by Kalyanasundaram et al. and others, restoring SR calcium uptake in acquired models of heart failure has a strong beneficial effect upon SR Ca 2+ physiology and the heart failure phenotype. This is multifaceted, including improvements in contractile function, myocardial energetics and survival, and reversal of the abnormalities of gene expression, microRNAs, and hypertrophy signalling, which promote heart failure progression. 8, 9 In contrast to increasing SR uptake in the CSQ knockout model, SERCA2a gene transfer or genetic SERCA2a overexpression, improves cardiomyocyte survival and reduces apoptosis in chronic heart failure, including diametrically opposite changes to the akt and apoptosis pathways to those reported by Kalyanasundaram et al. Myocardial SERCA2a gene transfer also reversed the acquired leak SR phenotype, by increasing SR Ca 2+ uptake as expected from the intervention, but also reducing RyR-mediated SR leak, and normalizing SR Ca 2+ load ( Figure 1B) . 10 This effect translated into improvements in cardiac contraction and relaxation, a reduction in delayed afterdepolarizations in vitro, and most importantly reduced spontaneous and catecholamine-provoked arrhythmias in vivo. At the molecular level, SERCA2a gene transfer reversed CaMKII-dependent phosphorylation of the RyR, 10 which is perhaps indicative of normalized dyadic [Ca 2+ ] ( Figure 1B ). This finding highlights the contrasting effects of SERCA up-regulation in acquired vs. genetic abnormalities of cardiomyocyte SR function. Beyond triggered activity, Cutler et al. 11 recently reported that SERCA2a gene transfer can eliminate Ca 2+ and repolarization alternans, and inducible ventricular fibrillation in a guinea pig model of heart failure. Therefore, in addition to targeting the 'leaky' SR substrate for ventricular arrhythmias, SERCA2a gene transfer also appears to modify the substrate of the failing heart at multiple scales, which synergistically impart an antiarrhythmic effect. Key to this is the ability to correct reversible abnormalities of SR physiology in the acquired heart failure which is not possible in the genetic conditions. Support for therapeutic benefits of increasing SERCA2a activity in acquired heart failure also comes from on-going clinical trials. Thirtyseven patients with advanced heart failure have received a single dose of recombinant adeno-associated adenovirus, expressing SERCA2a across an open-label phase 1 and a double-blinded phase 2 trial. 12 Most importantly, this strategy showed no signs of increased toxicity, with no evidence of increasing ventricular arrhythmias in this patient group potentially at risk of sudden cardiac death. The most striking finding was the consistent benefit across a number of relevant clinical parameters of heart failure, including death and hospitalization, in the highest dose arm receiving SERCA2a gene therapy. This has formed the platform for a larger 200 patient phase 2b trial which is currently enrolling (EudraCT:2012-001700-37). The answers from this study, and other trials using SERCA2a gene therapy or RyR stabilizers currently planned or underway, will be the most informative regarding the relevant effects of targeting the SR therapeutically.
Where will all these observations potentially lead the scientific and clinical community? The SR remains a fascinating and intriguing organelle within the cardiomyocyte, with many further facets still worthy of scientific exploration in the laboratory. The increasing knowledge base that SR dysfunction may contribute to the pathophysiology of a number of cardiac diseases, and the emerging ability to selectively target the SR in patients with these diseases, is slowly capturing the imagination and interest of the clinical cardiology community. The work of Kalyanasundaram et al confirms that a genetically determined augmentation of SR Ca 2+ leak has the potential to induce pathological remodelling, hypertrophy and heart failure, and in this context increasing SR Ca 2+ uptake only serves to exacerbate the problem. This exemplifies the notion that 'one size does not fit all' when it comes to designing new treatment strategies for the SR. In the dawning era of personalized medicine, one can perceive a standard of care involving a screen for genetic abnormalities of SR storage and release in patients with cardiac disease. Those cardiology patients with cardiac disease and a 'positive' or 'high risk' genetic result (e.g. CPVT) would require stratification to agents aimed at improving SR storage and reducing spontaneous SR release (e.g. RyR stabilizers, CaMKII inhibitors, CSQ gene therapy). Conversely patients without a high genetic risk, and a disease associated with acquired SR abnormalities (e.g. heart failure) would be suitable for a range of treatment options normalizing SR calcium uptake (SERCA2a gene therapy) and/or reducing SR leak (RyR stabilizers, CaMKII inhibitors). On the basis of the above discussion, we anticipate that such patient-specific therapies will optimize Ca 2+ physiology, thereby improving triggering of contraction, relaxation and signalling, and reducing arrhythmias. 
